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Edited by Barry HalliwellAbstract Administration of peptide YY3-36 (PYY3-36) to fasting
humans or mice shortly before re-feeding eﬀectively reduced their
food intake, but PYY3-36 exhibited a functional half-life of only
3 h. Attachment of poly(ethylene glycol) to proteins and pep-
tides (PEGylation) prolongs their half-life in vivo, but completely
inactivated PYY3-36. We developed a reversibly PEGylated
PYY3-36 derivative by coupling it to a 40 kDa PEG through
a spontaneously cleavable linker. The resulting conjugate
(PEG40–FMS–PYY3-36) gradually released unmodiﬁed PYY3-36
in vivo, exhibiting an eightfold increase in its functional half-life,
to 24 h. This long-acting PYY3-36 pro-drug may serve as an
eﬀective means for controlling food intake in humans.
 2005 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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The hypothalamic family of neuropeptide Y (NPY) recep-
tors regulate satiety and food intake [1]. The putative inhibi-
tory Y2 pre-synaptic receptor (Y2R) is expressed in the
arcuate nucleus, which is accessible to local and peripheral
agonists of the NPY family [2,3]. One such Y2R agonist is pep-
tide YY3-36 (PYY3-36), which is released from the gastrointes-
tinal tract following food intake in proportion to the caloric
content of a meal [4]. Several studies have demonstrated that
peripheral administration of PYY3-36 inhibits food intake in
humans, mice, and rats following a 24 h fast [5–7]. Thus, infu-
sion of PYY3-36 to reach the normal postprandial circulatory
concentrations of this peptide leads to a peak in serum
PYY3-36 within 15 min, followed by a rapid decline to basal
levels within 30 min. Despite this rapid clearance, administra-
tion of PYY3-36 to fasting individuals decreases their appetite
and reduces food intake by 33% within a 12 h period following
PYY3-36 administration. Furthermore, no compensatory foodAbbreviations: PYY3-36, peptide YY3-36; FMS, (2-sulfo)-9-ﬂuorenyl-
methoxycarbonyl; MAL–FMS–OSu, 9-hydroxymethyl-7-(amino-3-m-
aleimidoproprionate)-2-sulfo-ﬂuorene-N-hydroxysuccinimide; PEG40,
40 kDa-branched poly(ethylene glycol); PEG40–FMS–PYY3-36, a 1:1
conjugate of PEG40–FMS covalently attached to PYY3-36; PEG40–SH,
a 40 kDa-branched polyethylene glycol linked to cystamine
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were later challenged by a large multicenter study, which dem-
onstrated lack of eﬀect PYY3-36 in rodents [8]. One of these
studies did show, however, that continuous administration of
PYY3-36 reduced food intake in mice during the ﬁrst 3 days
of administration. Similarly, eﬀective inhibition of gastric emp-
tying, as well as food intake, was recently reported in rats dur-
ing continuous infusion of PYY3-36 [9,10].
The short circulatory half-life of PYY3-36 and the need for its
continuous administration prompted us to develop a longer-
acting version of PYY3-36. Covalent attachment of PEG to
proteins prolongs their half-life in vivo, but often leads to a
drastic loss of their biological or pharmacological activity
[11–18]. We found that PEGylation of PYY3-36 by standard
chemistry, i.e., through formation of a stable bond, led to its
complete inactivation. Here, we describe the development
and testing of a long-acting pro-drug of PYY3-36, obtained
by its reversible PEGylation.2. Materials and methods
2.1. Animals
C57Bl/6J male mice (Harlan labs) aged 9 ± 1 week (20–30 g body
weight) were used. Mice were kept under controlled temperature
(21–23 C) and light conditions (light on 6:00–18:00) at the animal
facility of the Weizmann Institute. The mice were acclimated for at
least one week prior to the initiation of the study. Mice had free access
to drinking water at all times during the experiments. All experimental
protocols were in accordance with the Israeli regulations for labora-
tory animal welfare and the Guide for the Care and Use of Laboratory
Animals as adopted and promulgated by the U.S. National Institutes
of Health.
2.2. Reagents
PYY3-36 was synthesized by the solid phase method, using a multi-
ple-peptide synthesizer AMS 422 (Abimed Analyzer-Technik Gmbh,
Langenfeld, Germany). The resulting peptide was HPLC-puriﬁed
and characterized by MALDI-TOF mass spectroscopy (MS) and N-
terminal protein micro-sequencing. All reagents and chemicals were
of analytical grade and were purchased from Sigma Chemical Co.
(Ness Ziona, Israel).
2.3. Analytical procedures
MALDI-TOF MS and Electro Spray MS were performed with Bru-
ker-Reﬂex-Reﬂectron model, Germany, and VG-platform-II electro-
spray single quadrupole mass spectrometer, Micro Mass, UK,
respectively. PYY3-36, 40 kDa-branched poly(ethylene glycol)
(PEG40)–(2-sulfo)-9-ﬂuorenylmethoxycarbonyl (FMS)–PYY3-36 and
PEG40 (40 kDa-branched poly(ethylene glycol)) were resolved by ana-
lytical HPLC (Lichrosorb RP-4 column, 4 · 250 mm, Merck). Buﬀer A
was 0.1% aq. triﬂuoroacetic acid (TFA) and Buﬀer B was 0.1% TFA inblished by Elsevier B.V. All rights reserved.
Fig. 1. Dose–response (A) of PYY3-36 and time-dependent reduction
in food intake (B) in mice. (A) Male C57BL6J mice (10 per group) were
deprived of food for 24 h. At time 23 h of the fast, the mice received a
s.c. injection of either saline (open bar) or the indicated doses of
PYY3-36 (hatched bars). At time 24 h, the mice were given an excess of
pre-weighed chow for 2 h. Drinking water was provided at all times.
The amount of food consumed per 10 mice during 2 h is shown as a
function of PYY3-36 dose. (B) Mice were similarly deprived of food and
either saline (open bar) or PYY3-36 (5 nmol/mouse, hatched bars) was
administered at the indicated times prior to the start of the re-feeding
period. Results shown represent an average of four identical experi-
ments, with 10 mice each.
2440 Y. Shechter et al. / FEBS Letters 579 (2005) 2439–244475% aq. acetonitrile. A gradient of 10–100% Buﬀer B was used over
50 min at a ﬂow rate of 1 ml/min. The retention times (Rt) of PYY3-36,
a 1:1 conjugate of PEG40–FMS covalently attached to PYY3-36
(PEG40–FMS–PYY3-36) and PEG40-9-sulfo-fulvene were 21.53, 39.03
and 44.39 min, respectively. Amino acid analyses were performed fol-
lowing 6 N HCl hydrolysis at 110 C for 24 h using a Dionex Auto-
matic amino acid analyzer, HP1090 (Palo Alto, CA). N-terminal
sequence analyses were performed with a Model 491A Procise Protein
sequencer (Applied Biosystems, Foster City, CA).
2.4. Synthesis of 9-hydroxymethyl-7-(amino-3-maleimidopropionate)-2-
sulfo-ﬂuorene-N-hydroxysuccinimide (MAL–FMS–OSu)
The synthesis was initiated from 9-hydroxymethyl-2-amino-ﬂuorene
[19] following three steps to give a 48% overall-yield. Details of the syn-
thesis will be published elsewhere (manuscript in preparation).
PEG40–SH was prepared by dissolving PEG40–OSu at a concentra-
tion of 40 mg/ml in an aqueous solution of cystamine hydrochloride
(1 M) that was titrated to pH 8.5 with aq. NaHCO3. The reaction
was carried out for 2 h at 25 C. The resulting product was dialyzed
overnight against 0.1 M NaHCO3, treated with DTT (30 mM, 25 C,
1 h) and then dialyzed against 0.01 M HCl. PEG40–SH was obtained
in 93% yield. It contains 1 mol sulfhydryl group per mole of PEG40,
as determined with dithiobis(2-nitrobenzoic acid) in the presence of so-
dium ascorbate (10 mM). PEG40–SH was kept at 20 C until use.
2.5. Synthesis of PEG40–FMS–PYY3-36
MAL–FMS–OSu (288 lg, 28.8 ll, from a fresh 10 mg/ml solution of
MAL–FMS–OSu in dimethyl formamide, twofold molar execess) was
added to a stirred solution of PYY3-36 (1 mg in 1.0 ml phosphate buf-
fer, 10 mM, pH 7.2, and 0.247 lMNa ascorbate). After 7 min, PEG40–
SH was added to obtain a ﬁnal concentration of 0.52 mM (2.1 M ex-
cess over the peptide). The reaction was carried out for 1 h and the
mixture was then dialyzed overnight against water. The resulting
PEG40–FMS–PYY3-36 was characterized by MALDI-TOF MS.
2.6. Synthesis of PEG40–FMS–glycine ethyl ester
To a stirred solution of PEG40–SH (0.25 mM in 0.1 M phosphate
buﬀer, pH 7.2, and 10 mM Na ascorbate), 292 lg MAL–FMS–Osu
was added (twofold molar excess over PEG40–SH). After 7 min, a
0.2 ml aliquot from a solution of 0.5 M glycine ethyl ester was added.
The reaction was carried out for 1 h and the mixture was then dialyzed
overnight against water. The resulting PEG40–FMS–glycine ethyl ester
was characterized and quantitated by its absorbance at 280 nm
(e280 = 21 200) and by the amount of glycine in the preparation follow-
ing acid hydrolysis of a 20 ll aliquot and amino acid analysis.
2.7. Synthesis of PEG40–PYY3-36
Irreversibly, PEGylated PYY3-36 was prepared by reacting PYY3-36
(1 mg/ml in 0.1 M phosphate buﬀer, pH 7.2) with four equivalents of
solid PEG40–OSu (43 mg). The reaction was carried out for 1 h and
the mixture was then dialyzed overnight against water. The conjugate,
thus, obtained contains one PEG40 residue per PYY3-36 molecule, as
determined by MALDI-TOF MS (PEG40–OSu, 43,626 Da; PYY3-36,
4047 Da; conjugate, 47 712 Da).
2.8. Measurements of food intake
Groups of 10 mice per cage were acclimated for 7 days in a room
with a controlled temperature and a 12 h light, 12 h dark cycle. Mice
were deprived of food for 24 h and then given excess pre-weighed stan-
dard pellets for a period of 2 h at the start of the dark cycle. Drinking
water was provided at all times. The mice received s.c. injections of
either saline (0.1 ml/mouse), native PYY3-36, or PYY3-36 derivatives
at the indicated doses and times within the 24 h fast, prior to the start
of the 2 h re-feeding period. A minimum interval of 1 h was maintained
between injection and re-feeding to minimize a stress-dependent de-
crease in food intake. At that time, the sawdust bedding was replaced
by a sheet of Whatmann 3MM paper to allow collection of un-con-
sumed food debris. Remaining food pellets and debris were combined
and weighed after the 2 h re-feeding period and the cumulative food
intake per 10 mice was calculated. Amounts of food intake in replicate
experiments were normalized according to the saline controls. Results
are expressed as food intake per 10 mice ± S.D. from two to ﬁve rep-
licate experiments, each done with a new group of mice.2.9. Statistical analysis
The signiﬁcance of diﬀerences in food consumption was determined
by the Students t test, using the total weight of food consumed by each
group of 10 mice as a single value. A saline-injected group of 10 mice
was included in each experiment as a control. A two-tailed, paired t
test was performed between the control and treated groups to minimize
external eﬀects on food intake.3. Results
3.1. Dose–response and duration of PYY3-36 eﬀect on food
intake in mice
To evaluate the duration and magnitude of the eﬀect of
PYY3-36 and its derivatives on food intake, we employed the
mouse re-feeding model consisting of 24 h starvation followed
by a re-feeding period of 2 h. Fig. 1A shows that PYY3-36
inhibited food intake in a dose-dependent manner. Mice
receiving either saline or PYY3-36 s.c. at a dose of 5 nmol/
mouse consumed 10.7 ± 1.26 g (saline) and 5.26 ± 1.47 g
(PYY3-36) chow per 10 mice (P < 0.001, N = 5 groups of 10
mice/group). These ﬁgures correspond to a 50% decrease in
food intake by the PYY3-36 groups, as compared with the con-
trol saline groups. Inhibition was statistically signiﬁcant at all
doses used including the lowest dose of 0.2 nmol/mouse
(P < 0.05, N = 3). The dose–response indicated a half-maximal
eﬀect of PYY3-36 at about 0.5 nmol/mouse (Fig. 1A).
We then determined the duration of the satiety induced by
s.c. administration of PYY3-36 (5 nmol/mouse) at diﬀerent
times prior to onset of re-feeding. The satiety induced by
PYY3-36 was maximal when given 1 h prior to re-feeding and
rapidly decreased when PYY3-36 was administered at earlier
times. The functional half-life of PYY3-36, deﬁned as the time
of administration prior to re-feeding that gives half-maximal
biological response, was about 3 h. No signiﬁcant eﬀect on
food intake was measured with 5 nmol PYY3-36 when admin-
istered 10 h prior to the re-feeding period (Fig. 1B).
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H3.2. PEGylation renders PYY3-36 inactive
We then attempted to extend the functional half-life of
PYY3-36 by conventional PEGylation using PEG40–OSu. The
resulting mono-PEGylated PEG40–PYY3-36 was administrated
s.c. to mice at the optimal time of 1 h prior to the re-feeding
period. It was found that mice injected with 5 nmol PEG40–
PYY3-36 per mouse ate 10.0 ± 0.2 g chow per 10 mice as com-
pared with 10.2 ± 1.4 g in the saline group and 5.1 ± 1.2 g in
the PYY3-36 group. These ﬁgures indicated that conventional
PEGylation, which results in a stable PEGylated peptide, abol-
ished the biological activity of PYY3-36. We then tested
whether the inactivation of PYY3-36 was due to the bulkiness
of the PEG group or due to blocking of the amino residues
of PYY3-36. Acetylation of the two amino groups of PYY3-36
largely abolished the ability of PYY3-36 to induce satiety in
vivo. Thus, mice injected with 20 lg Na-Ne-diacetyl-PYY3-36
per mouse ate 10.54 ± 0.08 g chow per 10 mice, as compared
with 10.6 ± 1.26 g in the saline group and 5.26 ± 1.47 g in the
PYY3-36 group. Hence, even attachment of a small acetyl
group to the two amino residues of PYY3-36 was suﬃcient to
disrupt its biological activity.CONH2
Fig. 2. Structure of MAL–FMS–OSu (A) and schematic representa-
tion of the steps involved in preparation of PEG40–FMS–PYY3-36 (B).3.3. Preparation and characterization of PEG40–FMS–PYY3-36
The lack of biological activity following PEGylation or even
acetylation of PYY3-36 prompted us to develop a reversibly
PEGylated conjugate of PYY3-36. Fig. 2 illustrates the steps in-
volved in preparing the PEG40–FMS–PYY3-36 conjugate.
MAL–FMS–OSu is an hetero-bi-functional agent, consisting
of sulfonated ﬂuorenylmethoxycarbonyl N-hydroxy-
succinimide ester that reacts with amino groups of peptides
and proteins (for structure, see Fig. 2A). A maleimide group
was attached to the ﬂuorenyl backbone, enabling its coupling
to the PEG40–SH. The procedure depicted in Fig. 2 was found
to be optimal for coupling equimolar amounts of PEG40–SH
and MAL–FMS–PYY3-36.
We next analyzed the reaction product by MALDI-TOFMS
to determine the molar ratio of PEG40 and PYY3-36. The
molecular mass of PYY3-36 was 4047.51 Da as determined by
MALDI-TOF MS (calcd. = 4049.6 Da). PEG40–SH had an
average molecular mass of 43 626 Da and the conjugate
yielded a major peak corresponding to a molecular mass of
47 712.6 Da (not shown). The calculated mass of the 1:1 con-
jugate of PEG40–SH and MAL–FMS–PYY3-36 is 48 087 Da.
Thus, the main product corresponds to a 1:1 conjugate of
PYY3-36 and PEG40.3.4. PEG40–FMS is linked to the a amino group of PYY3-36
PYY3-36 contains an N-terminal a-amino group of isoleucine
and one e-amino group (of lysine) at position 2, both of which
are potentially available for acylation by MAL–FMS–OSu. To
determine the site(s) of acylation, PEG40–FMS–PYY3-36 was
reacted with a 500-fold molar excess of acetic anhydride at
pH 7.0 for 1 h, followed by overnight dialysis against water.
The PEG40–FMS group was then removed by incubating theacetylated PEG40–FMS–PYY3-36 for 4 days at pH 8.5. The
product was then subjected to N-terminal protein sequence
analysis. As shown in Fig. 3, cycles 1, 2 and 3 yielded the ex-
pected amounts of isoleucine, e-acetyl lysine and proline,
respectively. This result indicated that the PEG40–FMS group
was primarily linked to the N-terminal a-amino group of
PYY3-36. No free lysine was found in cycle 2, conﬁrming the
results of MS, which exhibited only mono-derivatization of
PYY3-36 by the PEG40–FMS group.
3.5. PEG40–FMS–PYY3-36 hydrolyses to yield PYY3-36 under
physiological conditions
To evaluate the rate of PYY3-36 release from PEG40–FMS–
PYY3-36, we incubated the conjugate in phosphate buﬀer (pH
8.5, 0.1 M, 37 C). Aliquots were withdrawn at diﬀerent times
and subjected to analytical HPLC, using elution conditions
that resolve PEG40–FMS–PYY3-36 from PYY3-36. At pH 8.5,
the rate of FMS hydrolysis from FMS-peptides or proteins is
nearly identical to that observed in normal human serum
[20]. As shown in Fig. 4, PYY3-36 was released from the conju-
gate in a slow, nearly ﬁrst-order rate with a half-life of 5.3 h.
After 40 h, the cumulative amount of free PYY3-36 reached
79% of the input PEG40–FMS–PYY3-36 conjugate.
3.6. Hydrolysis of PEG40–FMS–PYY3-36 in mouse serum
We found that PYY3-36 undergoes rapid proteolysis in
normal mouse serum at 37 C with a half-life of 3 ± 0.7 min
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Fig. 3. PEG40–FMS is linked to the a-amino group of PYY3-36.
PEG40–FMS–PYY3-36 (100 lg) was acetylated by a 500 M excess of
acetic anhydride at pH 7.0, dialyzed, and incubated for 3 days at pH
8.5, 37 C to quantitatively remove the PEG40–FMS moiety. The
resulting acetylated PYY3-36 was then subjected to three cycles of N-
terminal protein sequence analysis. The sequence obtained was ile-(Ne-
acetyl)lys-pro. Sequence analysis of the native peptide yielded ile, lys,
and pro on cycles 1, 2, and 3, respectively (not shown).
Fig. 4. Kinetics of PYY3-36 release from PEG40–FMS–PYY3-36.
PEG40–FMS–PYY3-36 (750 lM in 0.1 M phosphate buﬀer, pH 8.5,
2 mM NaN3) was incubated at 37 C. Aliquots (100 ll) were with-
drawn at the indicated times and free PYY3-36 was measured by
HPLC. The cumulative amount of PYY3-36 released is shown as a
function of time. The amount of PYY3-36 in the initial conjugate was
determined by acid hydrolysis of a 20 ll aliquot, followed by amino
acid analysis.
Fig. 5. Rate of PEG40–FMS–PYY3-36 hydrolysis in normal mouse
serum. PEG40–FMS–PYY3-36 (0.5 lM) in normal mouse serum was
incubated at 37 C. Aliquots were withdrawn at the indicated times
and the amount of 2-PEG40-9-sulfo-fulvene released from PEG40–
FMS–PYY3-36 was determined by HPLC and taken for calculating the
rate of PEG40–FMS–PYY3-36 hydrolysis. Inset: PYY3-36 is rapidly
degraded in normal mouse serum at 37 C. PYY3-36 (50 nM) in normal
mouse serum was incubated at 37 C. At the indicated times, aliquots
(100 ll) were removed, de-proteinated by three volumes of ethanol,
and the quantity of PYY3-36 was determined in the supernatants by
HPLC.
2442 Y. Shechter et al. / FEBS Letters 579 (2005) 2439–2444(Fig. 5, inset). Therefore, the rate of PEG40–FMS–PYY3-36
hydrolysis in mouse serum was evaluated by measuring the
amount of 2-PEG40-9-sulfo-fulvene released during hydrolysis.
PEG40–FMS–PYY3-36 was incubated in normal mouse serum
at 37 C. Aliquots were withdrawn at diﬀerent times, ethanol
(3 vol) was added to precipitate serum proteins, and following
centrifugation, the amount of 2-PEG40-9-sulfo-fulvene was
measured in the supernatants by HPLC. As shown in Fig. 5,
hydrolysis of PEG40–FMS–PYY3-36 in normal mouse serum
at 37 C proceeded in a nearly ﬁrst-order rate with a half-life
of 7.0 ± 0.3 h.
3.7. PEG40–FMS–PYY3-36 exhibits long functional half-life in
mice
We then determined the duration of the eﬀects of PEG40–
FMS–PYY3-36 (5 nmol/mouse) on food intake. The functional
half-life of unmodiﬁed PYY3-36 as determined by the inhibition
of food intake at diﬀerent times after administration was
about 3 h (Fig. 1B). By comparison, the functional half-
life of PEG40–FMS–PYY3-36 was greatly extended. Mice given
PEG40–FMS–PYY3-36 18 h prior to re-feeding ate 4.7 ± 0.14 g
chow per 10 mice, a value representing a 52% reduction in food
intake as compared with the control (saline) group (P < 0.05).
A statistically signiﬁcant reduction of 27% in food intake was
also seen in mice given PEG40–FMS–PYY3-36 24 h prior to re-
feeding (P < 0.05; Fig. 6). Thus, the functional half-life of
PEG40–FMS–PYY3-36 was about 24 h, namely, eightfold long-
er than that of unmodiﬁed PYY3-36. In a control study, s.c.
administration of PEG40–FMS-glycine ethyl ester (5 nmol/
mouse) 15 h before re-feeding had no eﬀect whatsoever on
food intake as compared to saline (Fig. 6, right columns).
Fig. 6. PEG40–FMS–PYY3-36 exhibits extended functional half-life in
vivo. The feeding protocol described in Fig. 1A and B was repeated,
except that the mice received either saline (open bars), PEG40–FMS–
PYY3-36 (5 nmol/mouse, closed bars) or PEG40–FMS–glycine ethyl
ester (5 nmol/mouse, hatched bars) s.c. at the indicated times prior to
re-feeding. Results represent an average of three identical experiments.
Y. Shechter et al. / FEBS Letters 579 (2005) 2439–2444 24434. Discussion
Continuous infusion of PYY3-36 undisputedly reduces food
intake in rodents [8,10]. Although, we could reproduce the sati-
ety eﬀects of unmodiﬁed PYY3-36 in 24 h starved mice as orig-
inally reported [5,6], the rapid degradation of PYY3-36 in the
serum poses a serious limitation on its practical use. Therefore,
development of a long-acting version of a PYY3-36 pro-drug is
a practical alternative to its continuous infusion.
Covalent attachment of 40 kDa polyethylene glycol (PEG)
to proteins and peptides eﬀectively prevents kidney ﬁltration,
thereby prolonging the half-life of the resulting conjugates
from minutes to many hours [11–14]. In addition, PEGylation
protects the peptides from proteolysis by restricting access to
proteases [13,15–17]. However, unlike proteins, small peptides
are often inactivated by PEGylation, as a proportionally larger
section of their surface must remain accessible to enable recep-
tor binding. Indeed, we found that irreversible PEGylation of
PYY3-36 and even acetylation of PYY3-36 rendered it inactive.
Therefore, we considered an alternative approach based on
reversible PEGylation of PYY3-36.
Several approaches toward reversible PEGylation of pro-
teins and peptides were proposed [21]. They suﬀer, however,
from major potential drawbacks. For example, reliance on
enzymatic detachment of PEGs from conjugates by serum pro-
teases and/or esterases as a rate determining step [21–23] might
not yield desirable pharmacokinetic proﬁles in vivo and may
be subject to ﬂuctuations due to changes in enzyme availabil-
ity. Similarly, disulﬁde-bonded conjugates are not cleaved in
the non-reducing environment of body ﬂuids [24]. A reversibly
PEGylated conjugate, which retains an active moiety capable
of reacting with free SH groups, may result in complex unde-
sired cross-linking [25]. We, therefore, searched for a solution
incorporating two principles: (i) removal of the PEG would re-
lease the parental peptide or protein in an unmodiﬁed and ac-
tive form; (ii) hydrolysis would proceed at a constant rate and
in a predictable manner over many hours, without requirement
for any enzymatic activity and regardless of conditions in vivo.
Previously, we showed that attachment of FMS groups to
peptides and proteins resulted in peptide pro-drugs from whichthe FMS moieties are released in a spontaneous, slow, and
consistent manner under physiological conditions. As a result,
a constant concentration of unmodiﬁed parental peptide or
protein is maintained in the circulation [20,26,27]. The rate
of FMS hydrolysis is dictated exclusively by the pH and the
composition of the serum, two parameters that are maintained
in mammals in strict homeostasis [28]. However, attachment of
the relatively small FMS group to peptides such as PYY3-36
does not render them completely resistant to clearance, e.g.,
by ﬁltration through the kidney. Therefore, we have adapted
FMS chemistry for reversible PEGylation. The resulting
reversibly PEGylated 48 kDa PYY3-36 pro-drug exhibited a
functional half-life of 24 h in mice, namely 8 times longer than
the unmodiﬁed PYY3-36.
The satiety induced in mice by the reversibly PEGylated
PYY3-36 is similar to that obtained by continuous infusion of
PYY3-36 to rodents and oﬀers a practical means for utilization
of this agent for regulating food intake and possibly for the
control of human obesity.
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